[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"control\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:control":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,48,73,104,132,160],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":43,"leadSponsor":45,"locationsCount":4},"100612019","acute-effects-of-exercise-in-peripheral-arterial-disease-patients-100612019",false,"NCT07248137","Acute Effects of Exercise in Peripheral Arterial Disease Patients","Acute Effects of Different Physical Exercise Conditions in Patients With Peripheral Arterial Disease","VESSEL-FIT","Inclusion Criteria:\n\n* Be 18 years of age or older.\n* Patients diagnosed with peripheral arterial disease at grade IIa or IIb according to the Leriche-Fontaine classification.\n\nExclusion Criteria:\n\n* Patients with dementia or cognitive impairment.\n* Patients with recent major surgery (≤12 months) or lower limb amputations.\n* Patients institutionalized in healthcare facilities.\n* Patients dependent on a wheelchair.\n* Patients with any other condition contraindicating participation in an exercise program.","ALL","18 Years","100 Years",{"count":21,"type":22},16,"ESTIMATED","INTERVENTIONAL",[25],"NA","Peripheral arterial disease (PAD) affects over 200 million people worldwide and is caused by narrowing of the arteries. Intermittent claudication, characterized by pain when walking, is its main symptom. Despite the proven benefits of exercise, there is no optimal protocol for treatment. To analyze the effects of different exercise conditions on proteomic and physiological markers in patients with PAD and to determine their preferences regarding exercise conditions. A clinical cross-over study with four randomized experimental conditions (aerobic training, traditional strength training, circuit training and control) will be conducted. Patients with grade IIa-IIb PAD according to the Leriche-Le Fontaine scale will be recruited from the Department of Angiology and Vascular Surgery Department of the Hospital Clínico Universitario de Valladolid. In each experimental session, measurements of cardiorespiratory capacity, post-exercise oxygen debt, ankle-brachial index, blood flow, peripheral oxygen saturation, perceived exertion, heart rate variability and blood proteome changes will be performed.",[28,29,30,31],"Aerobic Physical Exercise","Traditional Strength Exercise","Circuit Strength Exercise","Control",[33,34,35,36],"Intermittent claudication","Proteomic markers","Vascular disease","Physiotherapy","NOT_YET_RECRUITING","2025-11-24",{"date":40,"type":41},"2025-12-01","ACTUAL",{"date":40,"type":22},{"date":44,"type":22},"2026-03-31",{"name":46,"class":47},"European University Miguel de Cervantes","OTHER",{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100529112","salivary-extracellular-vesicle-associated-lncrnas-in-heart-failure-seal-hf-100529112","NCT06169540","Salivary Extracellular Vesicle Associated lncRNAs in Heart Failure (SEAL-HF)","SEAL-HF","Inclusion Criteria CHF:\n\n* At least 18 years of age\n* Stable disease defined as CHF of any type, New York Heart Association (NYHA) functional class II\u002FIII\u002FIV, N-terminal pro-B-type natriuretic peptide (NT-proBNP) ≥600 pg\u002Fml if Left Ventricular Ejection Fraction (LVEF) ≤30%; ≥1000 pg\u002FmL if LVEF 31-35%; ≥2500 pg\u002FmL if EF \\>35%\n\nInclusion Criteria ADHF:\n\n* At least 18 years of age\n* Clinical signs and\u002For symptoms (including exertional or rest dyspnea, orthopnea or Paroxysmal Nocturnal Dyspnea (PND)) and N-terminal pro-BNP level \\> 1000 pg\u002FmL or BNP \\> 400 pg\u002Fml, OR Clinical evidence of congestion: X-ray evidence of pulmonary edema or pleural effusions, elevated Jugular Venous Pulse (JVP), lower extremity edema, or rales on pulmonary examination, right heart catheterization evidence of elevated filling pressures (Right Atrium (RA) pressure \\> 10 mmHg; Pulmonary Capillary Wedge Pressure (PCWP) \\> 18 mmHg) and clinical response to Intravenous (IV) diuretic therapy (as judged by a physician)\n\nInclusion Criteria control:\n\n* At least 18 years of age\n* Will\u002Fhave undergone an EP procedure in the EP lab\n\nExclusion Criteria:\n\n* Active pregnancy or lactation\n* Cardiac amyloidosis\n* Active malignancies",{"count":56,"type":22},90,"OBSERVATIONAL","The purpose of this study is to determine the relationship between the levels of Ribonucleic acid (RNA) circulating molecules, including ones in extracellular vesicles from different organs in the blood and in the saliva of patients with Acute Decompensated Heart Failure (ADHF) and Chronic Heart Failure (CHF) to see if a new, non-invasive diagnostic test can be developed for heart failure exacerbation.",[60,61,31],"CHF","ADHF","RECRUITING","2025-11-11",{"date":65,"type":41},"2025-11-13",{"date":67,"type":41},"2023-04-19",{"date":69,"type":22},"2027-12-31",{"name":71,"class":47},"Massachusetts General Hospital",1,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":81,"sex":17,"minAge":82,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":23,"phases":86,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":103},"100556511","a-randomized-controlled-trial-testing-the-effect-of-the-youth-mindful-awareness-program-on-negative-affect-ymap2-100556511","NCT06526052","A Randomized Controlled Trial Testing the Effect of the Youth Mindful Awareness Program on Negative Affect (YMAP2).","Targeting Negative Affect Through Mindfulness Training in Youth at Risk for Internalizing Problems (R33)","YMAP2","Inclusion Criteria:\n\n* Ages 12, 13, 14, 15, 16, 17\n* Parental Consent\n* Participant Assent\n* Live in Illinois, California, or Tennessee\n\nExclusion Criteria:\n\n* current diagnosis of an anxiety or depressive disorder with significant clinical impairment\n* current alcohol or substance use disorder\n* current serious suicidal ideation or behavior\n* lifetime diagnosis of bipolar disorder, schizophrenia, autism, conduct disorder, or developmental delay\n* reading level below 4th grade\n* not English speaking at a level that would allow them to participate in the intervention and assessments",true,"12 Years","17 Years",{"count":85,"type":22},360,[25],"The goal of this randomized clinical trial is to compare the effects of an online mindfulness program to an active supportive comparison condition and a no-intervention control group on reducing and preventing mood and anxiety symptoms in at-risk youth. Youth who are high on trait negative affect will be randomized to one of the three conditions. The primary outcomes of interest are reductions in momentary negative affect and internalizing problems in adolescents ages 12 to 17 years old. All participants will be evaluated prior to being randomized, after the 9-session intervention period, and at a 6-month follow-up.\n\nThe first hypothesis is that the mindfulness intervention will predict decreases in stressor-reactive momentary negative affect and internalizing symptoms. The second hypothesis is that changes in momentary negative affect will partially account for the effects of the mindfulness intervention on internalizing symptoms.",[89,31],"Prevention",[91,92,93],"Adolescents","Mindfulness","Internalizing","2025-08-14",{"date":96,"type":41},"2025-08-20",{"date":98,"type":41},"2024-04-01",{"date":100,"type":22},"2027-04",{"name":102,"class":47},"Vanderbilt University",3,{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":81,"sex":17,"minAge":18,"maxAge":111,"enrollmentInfo":112,"targetDuration":4,"studyType":23,"phases":114,"briefSummary":115,"conditions":116,"keywords":118,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":72},"100598335","evaluating-the-efficacy-of-a-text-messaging-based-shisha-smoking-cessation-intervention-100598335","NCT07070154","Evaluating the Efficacy of a Text Messaging-based Shisha Smoking Cessation Intervention","Evaluating the Efficacy of a Text Messaging-based Shisha Smoking Cessation Intervention for Young Adults in Hong Kong: A Randomised Controlled Pilot Trial","Inclusion Criteria:\n\n* young adults aged 18 to 35 years who are interested in quitting shisha\n* smoked shisha within the 30 days at the time of enrolment (current smoker)\n* smoked for more than twelve times in 12 months (i.e., on a monthly basis)22\n* able to read and communicate in Chinese or English\n* agree to utilise his\u002Fher own personal mobile or smartphone to send and receive messages\n\nExclusion Criteria:\n\n* scored 10 (''have already quitted'') on Contemplation Ladder assessment at baseline\n* unable to provide consent\n* unable to read and communicate in Chinese or English","35 Years",{"count":113,"type":22},100,[25],"The goal of this study is to evaluate the efficacy of a culture specific text-messaging based shisha smoking cessation intervention for young adults in Hong Kong. Participants in the intervention group will receive smartphone text messaging-based intervention and support that contained personalised messages with both text and visual elements over 6 weeks under a manualised programme. Participants in the control group will only receive a leaflet about the health risks of shisha smoking (the exact identical contents received by the participants in the intervention group at a session).\n\nAll participants will complete a self-administered questionnaire at baseline, 6th- and 12th-week on their self-reported shisha abstinences, knowledge on risk, readiness to quit and attitudes on shisha smoking",[117,31],"Intervention",[119,120,121,122],"shisha smoking","text-messaging based","cessation intervention","mHealth","2025-07-14",{"date":125,"type":41},"2025-07-17",{"date":127,"type":22},"2025-07-20",{"date":129,"type":22},"2026-07",{"name":131,"class":47},"The University of Hong Kong",{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":138,"eligibilityCriteria":139,"healthyVolunteers":81,"sex":17,"minAge":18,"maxAge":140,"enrollmentInfo":141,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":143,"conditions":144,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":72},"100479040","pre--and-post-operative-teg-indices-in-patients-with-or-without-adenocarcinoma-undergoing-surgical-resection-100479040","NCT05517811","Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection","Use of Viscoelastic Assays Beyond Coagulation: Pre- and Post-operative TEG","TEG","Inclusion Criteria:\n\n* new diagnosis by the providing physician of hepatopancreaticobiliary, esophageal, colorectal or lung adenocarcinoma will be eligible for enrollment in the study\n* 18 Years and older\n\nExclusion Criteria:\n\n* Under 18 years old\n* prisoners\n* those unable to provide informed consent\n* pregnant women\n* and those undergoing emergent or urgent operative intervention at the time of diagnosis","99 Years",{"count":142,"type":22},400,"The investigators hypothesize that abnormalities in thromboelastography (TEG) parameters in patients with liver, pancreas, biliary, esophageal, colorectal, and lung adenocarcinoma can serve as biomarkers for oncologic disease burden, cancer recurrence and overall survival as well as thrombotic and hemorrhagic post-operative complications. The investigators further hypothesize that there is histologic pathology correlates to pre-operative TEG abnormalities, and that it identifies patients with virulent tumor biology.",[145,146,147,148,31,149,150],"Liver Cancer","Esophageal Cancer","Colorectal Cancer","Lung Adenocarcinoma","Pancreas Cancer","Biliary Cancer","2025-01-27",{"date":153,"type":41},"2025-01-28",{"date":155,"type":41},"2022-06-26",{"date":157,"type":22},"2028-07-31",{"name":159,"class":47},"University of Colorado, Denver",{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":164,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":166,"targetDuration":4,"studyType":23,"phases":168,"briefSummary":169,"conditions":170,"keywords":175,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":72},"100525019","impact-of-the-implementation-of-a-telemedicine-program-on-patients-diagnosed-with-asthma-100525019","NCT06116292","Impact of the Implementation of a Telemedicine Program on Patients Diagnosed with Asthma","Inclusion Criteria:\n\n* Age ≥18 years with a diagnosis of asthma based on GEMA 5.2 2022.\n* Patients seen in the pulmonology service of the center.\n* Patients who have not previously received asthma education.\n* Capable of giving signed informed consent.\n\nExclusion Criteria:\n\n* Patient who does not have a mobile device with Android or IOS system.\n* Lack of minimum technological knowledge for the use of the application (ESTOI).\n* People who are participating or have participated in a clinical trial in the last 6 months.\n* Patients diagnosed with other respiratory diseases except for obstructive sleep apnea (OSA), Asthma-COPD overlap syndrome (ACOS).\n* Patients with palliative or severe chronic illnesses that limit their life expectancy.",{"count":167,"type":22},108,[25],"Introduction: Asthma is one of the most common chronic respiratory diseases worldwide. Despite the extensive knowledge of the condition and available therapeutic options, severe asthmatic patients have poor disease control in 50% of cases.\n\nObjective: To assess the impact of implementing a mobile application (ESTOI) in patients diagnosed with asthma on disease control, treatment adherence, and perceived quality of life.\n\nMethodology: A 52-week randomized clinical trial involving asthma patients receiving care at a highly specialized hospital in Spain. A total of 108 patients will be included and divided into two groups. The intervention group will receive more comprehensive monitoring than usual, including access to the ESTOI application. The Asthma Control Test (ACT) questionnaire will be used as the primary assessment variable. Other variables to be studied include the Inhaler Adherence Test (TAI), the number of exacerbations, peak expiratory flow, exhaled nitric oxide examination, hospital anxiety and depression scale, asthma quality of life questionnaire, forced spirometry parameters (FVC, FEV1, and reversibility), and analytical parameters (eosinophilia and IgE).",[171,172,173,174,31],"Asthma","Telemedicine","Adherence, Treatment","Quality of Life",[171,172,176,177,173],"Asthma Control","Quality of Live","2024-10-20",{"date":180,"type":41},"2024-10-22",{"date":182,"type":41},"2024-01-01",{"date":184,"type":22},"2026-12-31",{"name":186,"class":47},"Hospital Universitari de Bellvitge"]